Should I take low-dose aspirin for primary prevention?

ASPREE reframed primary-prevention aspirin: bleed risk outweighs benefit in most healthy adults.

Our read is Not Supported. The claim circulating publicly is not borne out by the evidence — a strong evidence base (80/100) and a working majority (78% consensus) point the other way. Spending $3/month and low effort on taking low-dose aspirin for primary prevention is not where we would direct attention; the strongest evidence-based reading is to skip it.

Pulled the public claims about taking low-dose aspirin for primary prevention from the proponents circulating the claim and weighed them against the more cautious voices (a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.

• 01Expert consensus: 78% — a working majority among the voices we track.
• 02Evidence strength: 80/100, which we read as a strong evidence base.
• 03Direction of effect: the controlled evidence does not support the claim made for taking low-dose aspirin for primary prevention; in places it points the opposite way.
• 04Source of the belief: extrapolation from mechanism, animal data, or surrogate markers rather than human outcomes.
• 05Downside accounting: the costs and risks are real while the demonstrated upside is not.

Talk to your doctor. This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so taking low-dose aspirin for primary prevention is not a casual decision. Loop in a clinician who can see your full history before starting.

A rigorous human RCT reversing the current null or harmful signal; absent that, the verdict stands.